(NVS) Novartis - Ratings and Ratios
Cardiovascular,Oncology,Immunology,Neuroscience,Hematology
NVS EPS (Earnings per Share)
NVS Revenue
Description: NVS Novartis
Novartis AG (NYSE: NVS) is a Swiss-based, globally integrated pharmaceutical company that researches, develops, manufactures, distributes, markets and sells prescription medicines across a broad therapeutic spectrum.
Key product highlights include Entresto for heart-failure with reduced ejection fraction, Cosentyx for psoriasis and related inflammatory diseases, Kisqali (CDK4/6 inhibitor) for breast cancer, Promacta/Revolade for immune-mediated thrombocytopenia, the Tafinlar + Mekinist combo for targeted oncology, and Jakavi for myelofibrosis and related disorders. Additional assets span Tasigna for chronic myeloid leukemia, Xolair for allergic asthma, Ilaris for autoinflammatory conditions, Pluvicto for metastatic castration-resistant prostate cancer, Sandostatin formulations for neuroendocrine tumors, Zolgensma for spinal muscular atrophy, Lucentis for retinal disease, Leqvio (inclisiran) for LDL-cholesterol reduction, Lutathera for neuroendocrine tumors, Scemblix and Fabhalta among others.
The company’s therapeutic focus is concentrated in cardiovascular-renal-metabolic, immunology, neuroscience, oncology and hematology, reflecting both the highest unmet-need areas and the segments with the strongest pipeline growth potential.
Novartis maintains a strategic partnership with Alnylam Pharmaceuticals to co-develop, manufacture and commercialize Leqvio, leveraging RNA-interference technology to expand its lipid-lowering franchise.
Financially, Novartis reported FY 2023 revenue of $51.6 billion, with an operating margin of 23 % and R&D expenditure of $9.6 billion, underscoring its commitment to pipeline renewal. The dividend yield hovered around 3.5 % and the company returned $8.0 billion to shareholders via buybacks and dividends, indicating a mature cash-generation profile.
Sector-level drivers that will likely shape Novartis’ outlook include an aging global population driving demand for chronic-disease therapies, continued pricing pressure in the United States, and accelerating adoption of advanced modalities such as gene-therapy and RNA-based medicines, which are reshaping competitive dynamics.
For a deeper quantitative assessment of Novartis’ valuation metrics, you may find the ValueRay platform useful.
NVS Stock Overview
| Market Cap in USD | 251,999m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1991-11-18 |
NVS Stock Ratings
| Growth Rating | 90.5% |
| Fundamental | 87.9% |
| Dividend Rating | 59.8% |
| Return 12m vs S&P 500 | 1.34% |
| Analyst Rating | 2.85 of 5 |
NVS Dividends
| Dividend Yield 12m | 3.03% |
| Yield on Cost 5y | 6.12% |
| Annual Growth 5y | 5.30% |
| Payout Consistency | 96.4% |
| Payout Ratio | 45.7% |
NVS Growth Ratios
| Growth Correlation 3m | 78.5% |
| Growth Correlation 12m | 88.9% |
| Growth Correlation 5y | 90% |
| CAGR 5y | 26.61% |
| CAGR/Max DD 3y (Calmar Ratio) | 1.33 |
| CAGR/Mean DD 3y (Pain Ratio) | 5.73 |
| Sharpe Ratio 12m | 0.53 |
| Alpha | 5.82 |
| Beta | 0.569 |
| Volatility | 18.22% |
| Current Volume | 1382.5k |
| Average Volume 20d | 1400.4k |
| Stop Loss | 127.8 (-3%) |
| Signal | 0.15 |
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income (9.62b TTM) > 0 and > 6% of Revenue (6% = 3.28b TTM) |
| FCFTA 0.16 (>2.0%) and ΔFCFTA 4.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -10.57% (prev -3.98%; Δ -6.59pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.20 (>3.0%) and CFO 20.79b > Net Income 9.62b (YES >=105%, WARN >=100%) |
| Net Debt (25.98b) to EBITDA (16.64b) ratio: 1.56 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.96b) change vs 12m ago -4.20% (target <= -2.0% for YES) |
| Gross Margin 82.08% (prev 74.10%; Δ 7.98pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 54.12% (prev 49.44%; Δ 4.67pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 14.15 (EBITDA TTM 16.64b / Interest Expense TTM 840.3m) >= 6 (WARN >= 3) |
Altman Z'' 2.43
| (A) -0.06 = (Total Current Assets 25.94b - Total Current Liabilities 31.71b) / Total Assets 104.39b |
| (B) 0.40 = Retained Earnings (Balance) 41.53b / Total Assets 104.39b |
| (C) 0.12 = EBIT TTM 11.89b / Avg Total Assets 100.95b |
| (D) 0.67 = Book Value of Equity 42.02b / Total Liabilities 62.34b |
| Total Rating: 2.43 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 87.89
| 1. Piotroski 9.0pt = 4.0 |
| 2. FCF Yield 6.05% = 3.02 |
| 3. FCF Margin 30.76% = 7.50 |
| 4. Debt/Equity 0.78 = 2.21 |
| 5. Debt/Ebitda 1.56 = 0.84 |
| 6. ROIC - WACC (= 9.34)% = 11.68 |
| 7. RoE 22.94% = 1.91 |
| 8. Rev. Trend 30.75% = 2.31 |
| 9. EPS Trend 88.39% = 4.42 |
What is the price of NVS shares?
Over the past week, the price has changed by +2.07%, over one month by +6.83%, over three months by +15.46% and over the past year by +17.98%.
Is Novartis a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NVS is around 150.06 USD . This means that NVS is currently undervalued and has a potential upside of +13.86% (Margin of Safety).
Is NVS a buy, sell or hold?
- Strong Buy: 0
- Buy: 2
- Hold: 9
- Sell: 0
- Strong Sell: 2
What are the forecasts/targets for the NVS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 122.1 | -7.4% |
| Analysts Target Price | 122.1 | -7.4% |
| ValueRay Target Price | 165.3 | 25.5% |
Last update: 2025-10-13 02:03
NVS Fundamental Data Overview
P/E Trailing = 18.9272
P/E Forward = 14.1844
P/S = 4.5664
P/B = 6.0388
P/EG = 1.3644
Beta = 0.569
Revenue TTM = 54.63b USD
EBIT TTM = 11.89b USD
EBITDA TTM = 16.64b USD
Long Term Debt = 22.47b USD (from longTermDebt, last quarter)
Short Term Debt = 8.57b USD (from shortTermDebt, last quarter)
Debt = 32.64b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 25.98b USD (from netDebt column, last quarter)
Enterprise Value = 277.98b USD (252.00b + Debt 32.64b - CCE 6.66b)
Interest Coverage Ratio = 14.15 (Ebit TTM 11.89b / Interest Expense TTM 840.3m)
FCF Yield = 6.05% (FCF TTM 16.81b / Enterprise Value 277.98b)
FCF Margin = 30.76% (FCF TTM 16.81b / Revenue TTM 54.63b)
Net Margin = 17.60% (Net Income TTM 9.62b / Revenue TTM 54.63b)
Gross Margin = 82.08% ((Revenue TTM 54.63b - Cost of Revenue TTM 9.79b) / Revenue TTM)
Gross Margin QoQ = 99.98% (prev 76.31%)
Tobins Q-Ratio = 2.66 (Enterprise Value 277.98b / Total Assets 104.39b)
Interest Expense / Debt = 0.00% (Interest Expense 289.0k / Debt 32.64b)
Taxrate = 0.01% (507.0k / 4.60b)
NOPAT = 11.88b (EBIT 11.89b * (1 - 0.01%))
Current Ratio = 0.82 (Total Current Assets 25.94b / Total Current Liabilities 31.71b)
Debt / Equity = 0.78 (Debt 32.64b / totalStockholderEquity, last quarter 41.98b)
Debt / EBITDA = 1.56 (Net Debt 25.98b / EBITDA 16.64b)
Debt / FCF = 1.55 (Net Debt 25.98b / FCF TTM 16.81b)
Total Stockholder Equity = 41.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.21% (Net Income 9.62b / Total Assets 104.39b)
RoE = 22.94% (Net Income TTM 9.62b / Total Stockholder Equity 41.93b)
RoCE = 18.46% (EBIT 11.89b / Capital Employed (Equity 41.93b + L.T.Debt 22.47b))
RoIC = 16.52% (NOPAT 11.88b / Invested Capital 71.93b)
WACC = 7.18% (E(252.00b)/V(284.64b) * Re(8.11%) + D(32.64b)/V(284.64b) * Rd(0.00%) * (1-Tc(0.00)))
Discount Rate = 8.11% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.58%
[DCF Debug] Terminal Value 78.85% ; FCFE base≈14.77b ; Y1≈15.60b ; Y5≈18.45b
Fair Price DCF = 164.9 (DCF Value 319.32b / Shares Outstanding 1.94b; 5y FCF grow 6.12% → 3.0% )
EPS Correlation: 88.39 | EPS CAGR: 16.77% | SUE: 0.48 | # QB: 0
Revenue Correlation: 30.75 | Revenue CAGR: 3.93% | SUE: 0.37 | # QB: 0
Additional Sources for NVS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle